 |
 |

Reductions in Occipital Cortex GABA Levels in Panic Disorder Detected With 1H-Magnetic Resonance Spectroscopy
Andrew W. Goddard, MD;
Graeme F. Mason, PhD;
Ahmad Almai, MD;
Douglas L. Rothman, PhD;
Kevin L. Behar, PhD;
Ognen A. C. Petroff, MD;
Dennis S. Charney, MD;
John H. Krystal, MD
Arch Gen Psychiatry. 2001;58:556-561.
Background There is preclinical evidence and indirect clinical evidence implicating -aminobutyric
acid (GABA) in the pathophysiology and treatment of human panic disorder.
Specifically, deficits in GABA neuronal function have been associated with
anxiogenesis, whereas enhancement of GABA function tends to be anxiolytic.
Although reported peripheral GABA levels (eg, in cerebrospinal fluid and plasma)
have been within reference limits in panic disorder, thus far there has been
no direct assessment of brain GABA levels in this disorder. The purpose of
the present work was to determine whether cortical GABA levels are abnormally
low in patients with panic disorder.
Methods Total occipital cortical GABA levels (GABA plus homocarnosine) were
assessed in 14 unmedicated patients with panic disorder who did not have major
depression and 14 retrospectively age- and sex-matched control subjects using
spatially localized 1H-magnetic resonance spectroscopy. All patients
met DSM-IV criteria for a principal current
diagnosis of panic disorder with or without agoraphobia.
Results Patients with panic disorder had a 22% reduction in total occipital
cortex GABA concentration (GABA plus homocarnosine) compared with controls.
This finding was present in 12 of 14 patient-control pairs and was not solely
accounted for by medication history. There were no significant correlations
between occipital cortex GABA levels and measures of illness or state anxiety.
Conclusions Panic disorder is associated with reductions in total occipital cortex
GABA levels. This abnormality might contribute to the pathophysiology of panic
disorder.
From the Departments of Psychiatry (Drs Goddard, Mason, Almai, and
Krystal), Biomedical Engineering (Dr Mason), Internal Medicine (Dr Rothman),
Radiology (Dr Rothman), and Neurology (Drs Behar and Petroff), Yale University
School of Medicine, New Haven, Conn; and the National Institute of Mental
Health, Rockville, Md (Dr Charney).
Corresponding author and reprints: Andrew W. Goddard, MD, Yale Anxiety
Clinic, Yale Department of Psychiatry, 100 York St, Room 2J, New Haven, CT
06511 (e-mail: andrew.goddard{at}yale.edu).
|